The long road to developing the first TCR-T therapy

Adaptimmune, a UK-based biotech firm focused on T-cell receptor (TCR) therapies for cancer, is set to launch its first FDA-approved therapy, afami-cel, marketed as Tecelra. Despite difficulties with previous partnerships, a collaboration with Belgian biotech company Galapagos is providing significant funding for the launch. Afami-cel is the first approved engineered cell therapy for solid tumors and the most expensive per-dose cellular medicine for cancer in the US, priced at $727,000.